Оголошено лауреатів Нобелівської премії з фізіології та медицини

Investment of 350 million EUR in state-of-the-art research infrastructure is Boehringer Ingelheim’s largest single investment in Germany to date Boehringer Ingelheim strengthens innovation power and development of biopharmaceuticals, which account…

Novartis’ Sandoz spinoff is right around the corner, and, to celebrate the occasion, the Swiss pharma is plotting a special stock distribution scheme. Roughly a year after disclosing plans to…